<!--https://www.openaustralia.org.au/senate/?id=2017-02-15.120.2-->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
 <head>
  <meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
  <title>
   Transvaginal Mesh Implants: 15 Feb 2017: Senate debates (OpenAustralia.org)
  </title>
  <meta content="Making parliament easy." name="description"/>
  <meta content="Parliament, government, House of Representatives, Senate, Senator, MP, Member of Parliament, MPs, Australia, Australian, Transvaginal Mesh Implants: 15 Feb 2017" name="keywords"/>
  <meta content="5FBaCDi8kCKdo4s64NEdB5EOJDNc310SwcLLYHmEbgg=" name="verify-v1"/>
  <meta content="width=device-width; initial-scale=1.0; maximum-scale=1.0" name="viewport">
   <link href="mailto:contact@openaustralia.org" rel="author" title="Send feedback"/>
   <link href="http://www.openaustralia.org.au/" rel="home" title="Home"/>
   <link href="/" rel="start" title="Home"/>
   <!-- skin: mobile -->
   <link href="/style/default/global_non_ns4_mobile.css" rel="stylesheet" type="text/css"/>
   <link href="/style/default/mobile.css" rel="stylesheet" type="text/css"/>
   <link href="/style/default/print.css" media="print" rel="stylesheet" type="text/css"/>
   <script type="text/javascript">
    var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
   </script>
   <script type="text/javascript">
    var pageTracker = _gat._getTracker("UA-3107958-3");
pageTracker._initData();
pageTracker._trackPageview();
   </script>
  </meta>
 </head>
 <body>
  <div id="container">
   <a name="top">
   </a>
   <div id="banner">
    <div id="title">
     <h1>
      <a href="/" title="To the front page of the site">
       <img alt="OpenAustralia.org beta" height="32" src="/images/openaustraliaorgbeta.gif" width="262"/>
      </a>
     </h1>
    </div>
   </div>
   <!-- end #banner -->
   <div id="content">
    <div class="stripe-head-1">
     <div class="main">
      <h2>
       Senate debates
      </h2>
      <h3>
       Wednesday, 15 February 2017
      </h3>
      <h4>
       Motions
      </h4>
      <h5>
       Transvaginal Mesh Implants
      </h5>
      <p>
       3:58 pm
      </p>
      <a name="g120.3">
      </a>
      <p class="speaker">
       <a href="/senator/?m=100858" title="See more information about Derryn Hinch">
        <img alt="Photo of Derryn Hinch" class="portrait" src="/images/mps/10852.jpg"/>
        <strong>
         Derryn Hinch
        </strong>
       </a>
       <small>
        (Derryn Hinch's Justice Party) |
        <a href="http://parlinfo.aph.gov.au/parlInfo/search/display/display.w3p;adv=yes;orderBy=_fragment_number,doc_date-rev;page=0;query=Dataset%3Ahansards,hansards80%20Date%3A15%2F2%2F2017;rec=0;resCount=Default" title="The source of this piece of text">
         Hansard source
        </a>
       </small>
       <p>
        I, and also on behalf of Senators Leyonhjelm, Lambie and Griff, move:
       </p>
       <p class="italic">
        That the following matter be referred to the Community Affairs References Committee for inquiry and report by 30 November 2017:
       </p>
       <p class="italic">
        (1) The number of women in Australia:
       </p>
       <p class="italic">
        (a) who have had transvaginal mesh implants;
       </p>
       <p class="italic">
        (b) who have had transvaginal mesh implants who have experienced adverse side effects; and
       </p>
       <p class="italic">
        (c) who have made attempts to have the mesh removed in Australia or elsewhere.
       </p>
       <p class="italic">
        (2) Information provided to women prior to surgery about possible complications and side effects.
       </p>
       <p class="italic">
        (3) Information provided to doctors regarding transvaginal mesh implants and possible complications and side effects.
       </p>
       <p class="italic">
        (4) Any financial or other incentives provided to medical practitioners to use or promote transvaginal mesh implants.
       </p>
       <p class="italic">
        (5) The types and incidence of health problems experienced by women with transvaginal mesh implants and the impact these health problems have had on women's lives.
       </p>
       <p class="italic">
        (6) The Therapeutic Goods Association's:
       </p>
       <p class="italic">
        (a) role in investigating the suitability of the implants for use in Australia;
       </p>
       <p class="italic">
        (b) role in ongoing monitoring of the suitability of the implants; and
       </p>
       <p class="italic">
        (c) knowledge of women suffering with health problems after having transvaginal mesh implants.
       </p>
       <p class="italic">
        (7) Options available to women to have transvaginal mesh removed.
       </p>
       <p class="italic">
        (8) Any other related matters.
       </p>
       <br/>
       <br/>
       <br/>
       <br/>
       <div id="footer">
        <p>
         <a href="/?show_pc">
          View the PC OA website
         </a>
        </p>
       </div>
      </p>
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
